Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 983

Results For "ED"

9932 News Found

Glenmark launches Ryaltris-AZ at affordable price
News | May 04, 2021

Glenmark launches Ryaltris-AZ at affordable price

First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg


RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21
News | May 03, 2021

RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21

The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021


Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.


Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr
News | May 03, 2021

Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr

Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21


India to import 450,000 vials of Remdesivir
News | May 01, 2021

India to import 450,000 vials of Remdesivir

The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country


Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine
News | April 30, 2021

Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine

New agreement for three further production lines at Lonza’s site in Visp, Switzerland


Indian vaccine players to garner Rs. 70,599 Cr in 2021
News | April 30, 2021

Indian vaccine players to garner Rs. 70,599 Cr in 2021

Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong


Cipla signs agreement with Merck for Molnupiravir
News | April 29, 2021

Cipla signs agreement with Merck for Molnupiravir

Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19


Biocon and Viatris receive EC approval for Biosimilar Bevacizumab
Biotech | April 28, 2021

Biocon and Viatris receive EC approval for Biosimilar Bevacizumab

The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer


Govt. approves 25 manufacturing sites for Remdesivir production
News | April 26, 2021

Govt. approves 25 manufacturing sites for Remdesivir production

The production capacity is now ramped up to 90 lakh vials per month whereas earlier it was 40 lakh vials/month